Alentis Therapeutics
PrivateLast Round
Series D
Nov 12, 2024
Est. Valuation
$2B
Total Funding Raised
$365.9M
Momentum
Top 25%
of companies Caplight tracks
Company Overview
Alentis Therapeutics operates in Healthcare & Life Sciences and is based in Allschwil. Its latest recorded funding round was a Series D round in November 2024.
Alentis Therapeutics is a biotechnology company that develops innovative treatments for cancer and fibrotic diseases by targeting Claudin-1.
Sector
Healthcare & Life Sciences
Verticals
Biotechnology, Drug Discovery, Clinical Trials
Business Model
B2B
Customer Profile
Services & Consulting
AI Layer
Non-AI
Historical Pricing
Historical view of private secondary pricing and transaction trends.
Alentis Therapeutics Comparables
Compare Alentis Therapeutics with similar companies based on industry and business-model similarity.
| Company | Similarity | Market Cap |
|---|---|---|
| TORL BioTherapeutics | 78% | |
| Adcendo | 74% | |
| Sotio | 72% |
For institutional investors. Book with your work email.
Alentis Therapeutics Funding Rounds
Historical fundraising activity
| Round | Date | Amount Raised | Valuation | Investors | Sources |
|---|---|---|---|---|---|
| Series D | Nov 12, 2024 | ||||
| Series C | Apr 13, 2023 | ||||
| Series B | Jun 15, 2021 | ||||
| Series A | Apr 30, 2019 |
For institutional investors. Book with your work email.
Key People
Founding team and executive leadership
For institutional investors. Book with your work email.
Alentis Therapeutics Investors
Notable investors and investment history
| Investor | Rounds |
|---|---|
| Longitude Capital | Series D |
| Avego Management | Series D |
| BioMedPartners | Series A, Series B |
| RA Capital Management | Series D, Series C |
| Heartland Healthcare Capital | Series D |
| Morningside Ventures | Series B |
| OrbiMed | Series D |
For institutional investors. Book with your work email.
Market signals
Structured signals derived from secondary market and firmographic data.
- Aug 22, 2026
Monthly visitors grew 35% MoM, reaching 5.3K.
- Jun 18, 2026
Monthly visitors grew 164% MoM, reaching 6.4K.
For institutional investors. Book with your work email.
Recent news
Latest coverage and updates
- is_developingOct 15, 2026
On Oct 14th '26 in Switzerland and Korea, Alentis and PinotBio announce a research collaboration and licensing agreement to discover and develop next-generation claudin-1-targeting ADCs for oncology, combining PinotBio’s novel linkers and payloads with Alentis’s antibody portfolio to address resistance mechanisms and unmet needs.
- partners_withOct 14, 2026
Alentis and PinotBio, Inc. partner through a research collaboration and licensing agreement to develop claudin-1-targeting ADCs by combining antibody and ADC technologies for cancers with significant unmet needs on Oct 14th '26.
- is_developingOct 14, 2026
Alentis is developing claudin-1-targeted treatments across oncology and fibrosis with PinotBio, and two investigational ADC candidates are already in Phase 1/2 clinical studies.
- is_developingOct 6, 2026
On Oct 6th '26, Alentis partners with CSL to develop lixudebart, an investigational therapy in early-stage studies for ANCA-associated vasculitis and rapidly progressive glomerulonephritis.
- is_developingOct 6, 2026
Alentis is developing lixudebart with CSL as an antifibrotic therapy for multiple rare kidney and liver diseases, with the drug currently in the Phase II RENAL trial for AAV-RPGN and planned Phase III development.
For institutional investors. Book with your work email.
Alentis Therapeutics Filings
Explore SEC and related filing metadata, where available.
| Type | Date | Amount Offered | Amount Sold | Filing | Pages | Download |
|---|
Filing documents are not displayed on this public page. Request access to learn about available coverage.
Book a demoFor institutional investors. Book with your work email.
Frequently Asked Questions
Common questions about Alentis Therapeutics's valuation, stock price, and market status.
Is Alentis Therapeutics a public or private company?
Alentis Therapeutics is a private company.
What is the current stock price of Alentis Therapeutics?
Alentis Therapeutics is a private company, so its shares have no public market price. Caplight tracks Alentis Therapeutics's secondary market activity and provides MarketPrice™ estimates of its share price to Caplight users.
How much is Alentis Therapeutics worth (valuation)?
Alentis Therapeutics's valuation is estimated at $2.0B based on funding round data.
Can I buy Alentis Therapeutics stock?
Alentis Therapeutics shares may be available on secondary markets subject to transfer restrictions. Caplight facilitates secondary market transactions for accredited investors.
When was Alentis Therapeutics's last funding round?
Alentis Therapeutics's most recent funding round was Series D on November 12, 2024.
Who are the main investors in Alentis Therapeutics?
Key investors in Alentis Therapeutics include BioMedPartners, RA Capital Management, Morningside Ventures, OrbiMed, Novo Holdings.
Will Alentis Therapeutics IPO soon?
No public IPO plans have been announced for Alentis Therapeutics.
How can I track Alentis Therapeutics secondary market activity?
Caplight tracks bids, offers, and trades in Alentis Therapeutics's shares on secondary markets.